Write TREMFYA®. Get TREMFYA®.

After considering the efficacy and safety of TREMFYA® for adult patients with moderate to severe plaque psoriasis

Tremfya® (guselkumab)



of commercially insured patients have preferred* access for TREMFYA®†‡

A dedicated TREMFYA withMe Guide can work one-on-one with eligible, non-commercially insured patients to answer questions about prescription fulfillment and help find financial assistance options.

Once a decision has been made to prescribe TREMFYA®, enroll patients in

Tremfya withMe

Personalized support for your patients and education for your office

- 1:1 Dedicated patient Guide
- Access & affordability support
- Specialty pharmacy enhanced services
- Field reimbursement & access specialists (FRAS)

Enroll your patients with a TREMFYA withMe Guide today

https://www.tremfyawithme.com/healthcare-professionals

Source: Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of August 2022.
*Preferred means TREMFYA® is available on the plan's formulary and may require a step edit.
†Within 2% of actual access.
‡This may not represent 100% of lives due to data limitations.
If a patient has been prescribed TREMFYA® for approved on-label use and is 18 or older, they are eligible for this program.
For those eligible, TREMFYA withMe is completely free. Eligibility for program components may vary.

Indication

TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Important safety information

CONTRAINDICATIONS

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please see the accompanying full Prescribing Information for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

janssen Immunology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson